A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects

Inclusion Criteria: * BMI between 18.0 and 32.0 kg/m2 * Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions Exclusion Criteria: * Subjects who do not agree to use a method of acceptable contraception * Female subjects of child-bearing potential who do not agree to use a highly effective method of birth control * Consume more than 28 or 21 units of alcohol per week if male or female, respective * Subjects who have used nicotine-containing products (including cigarettes), within 3 months prior to the first dose administration * Subjects who have used, or intend to use the product like non-prescribed systemic or topical medication, herbal remedy, vitamin/mineral supplement, within 7 days of the first dose administration * Systolic blood pressure \< 90 mmHg or \> 140 mmHg * Diastolic blood pressure \< 50 mmHg or \> 90 mmHg * Pulse rate \< 45 bpm or \> 100 bpm * Positive urine drugs of abuse screen at screening or first admission * Positive alcohol breath test at screening or first admission * Positive cotinine test at screening or first admission * Abnormality in the 12-lead ECG at screening, admission or predose on Day 1 * Subjects who are pregnant, breastfeeding, or lactating * Subjects who are still participating in another clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of any investigational drug in the past 3 months prior to the first dose administration * Subjects who have a significant history of drug allergy, as determined by the Investigator * Aspartate aminotransferase and/or Alanine aminotransferase ≥ 1.5 × upper limit of normal (ULN) or total bilirubin \> ULN at screening or admission * Subjects who are carriers of HBsAg or hepatitis C antibody, have serum hepatitis or positive result for the test for HIV antibodies